FDA Oks Cardiac Insight’s wearable ECG device

The Food and Drug Administration on Thursday gave market clearance to Cardiac Insight’s wearable electrocardiogram sensor, Cardea Solo.

Advertisement

Cardea Solo is a small, lightweight, disposable sensor patients can wear under their clothes for up to one week. The device collects and analyzes ECG data to help clinicians quickly diagnose arrthymias or heart issues.

Cardiac Insights expects the device to decrease the average time for cardiac diagnosis and treatment.

More articles on supply chain:

Global pharmerging market to reach $1.4B by 2025
Price hikes likely added $8.7B to pharma’s net income for 2016, report finds
ASCO: Strategies to control drug costs hinder cancer patient care

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.